Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session - CNS tumours

343MO - Clinical features and DNA methylation patterns in long- and short-term survivors of WHO grade II-III glioma

Date

20 Sep 2021

Session

Mini oral session - CNS tumours

Topics

Translational Research;  Survivorship;  Supportive and Palliative Care

Tumour Site

Central Nervous System Malignancies

Presenters

Maximilian Mair

Citation

Annals of Oncology (2021) 32 (suppl_5): S516-S529. 10.1016/annonc/annonc674

Authors

M.J. Mair1, E. Tomasich1, G. Heller1, L. Müller1, A. Wöhrer2, B. Kiesel3, G. Widhalm3, K. Dieckmann4, J.A. Hainfellner2, M. Preusser1, A.S. Berghoff1

Author affiliations

  • 1 Division Of Oncology, Department Of Medicine I, Medical University of Vienna, 1090 - Vienna/AT
  • 2 Division Of Neuropathology And Neurochemistry, Department Of Neurology, Medical University of Vienna, 1090 - Vienna/AT
  • 3 Department Of Neurosurgery, Medical University of Vienna, 1090 - Vienna/AT
  • 4 Department Of Radiation Oncology, Medical University of Vienna, 1090 - Vienna/AT

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 343MO

Background

WHO grade II-III gliomas affect rather young individuals and are characterized by a heterogenous survival prognosis ranging from months to years. Postoperative treatment prolongs survival but potentially impacts long-term quality of life and cognitive functioning. Therefore, refined prognostic stratification models are needed to guide future treatment studies.

Methods

Patients with histological diagnosis of WHO grade II/III glioma (lower-grade glioma, LGG) and treated in 2000 – 2018 at the Medical University of Vienna were identified. Short-term survivors (STS) were defined by OS < 12 months, while long-term survivors (LTS) were defined by OS > 10 years after diagnosis. Histological diagnosis according to the current WHO classification was done by a board-certified neuropathologist. DNA methylation profiling was performed using the Illumina EPIC 850k platform and methylation-based tumor classification was obtained using the Heidelberg Methylation Classifier.

Results

Among 599 LGG patients, 123 LTS (20.5%; 40/123 astrocytic, 44/123 oligodendroglial, 39/123 not otherwise specified or pre-WHO 2016 diagnosis = NOS) and 36 STS (6.0%, 24/36 astrocytic, 1/36 oligodendroglial, 11/36 NOS) were identified. At LGG diagnosis, Karnofsky Performance Scale (KPS) was lower (p < 0.001) and age was higher in STS as compared to LTS (p < 0.001). Epileptic seizures were more frequent in LTS, while motor deficits (p < 0.001), aphasia (p = 0.025) and visual disturbances (p = 0.031) were more common in STS at diagnosis. WHO grade II, IDH mutations, 1p19q codeletions and MGMT promoter methylation were each more frequent in LTS than in STS (p < 0.001). Unsupervised clustering of patient samples based on their methylome revealed 3 clusters. Cluster A included LTS with IDH-mutated tumors (n = 42, 68.9%). Cluster B was defined by STS with IDH-wildtype gliomas (n = 16, 26.2%). Cluster C comprised STS with IDH-mutated tumors (n = 3, 4.9%). Age, KPS and symptomatic burden did not differ between IDH-mutated tumors of clusters A and C (p > 0.05).

Conclusions

Our data indicate that DNA methylation profiling identifies IDH-mutated LGG with unfavorable prognosis. Further studies are needed to elucidate the pathobiology and optimal treatment of these high-risk LGG.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

M. Preusser: Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: Bayer; Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: Bristol-Myers Squibb; Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: Novartis; Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: Gerson Lehrman Group (GLG); Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: CMC Contrast; Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: GlaxoSmithKline; Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: Mundipharma; Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: Roche; Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: BMJ Journals; Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: MedMedia; Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: AstraZeneca; Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: AbbVie; Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: Lilly; Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: Medahead; Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: Daiichi Sankyo; Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: Sanofi; Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: Merck Sharp & Dohme; Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: Tocagen; Financial Interests, Institutional, Funding: Boehringer Ingelheim; Financial Interests, Institutional, Funding: Bristol-Myers Squibb; Financial Interests, Institutional, Funding: Roche; Financial Interests, Institutional, Funding: Daiichi Sankyo; Financial Interests, Institutional, Funding: Merck Sharp & Dohme; Financial Interests, Institutional, Funding: Novocure; Financial Interests, Institutional, Funding: GlaxoSmithKline; Financial Interests, Institutional, Funding: AbbVie. A.S. Berghoff: Financial Interests, Personal, Research Grant: Daiichi Sankyo; Financial Interests, Personal, Research Grant: Roche; Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: Roche; Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: Bristol-Myers Squibb; Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: Merck; Financial Interests, Personal, Other, Lectures, consultation or advisory board participation: Daiichi Sankyo; Financial Interests, Personal, Funding, Travel support: Roche; Financial Interests, Personal, Funding, Travel support: Amgen; Financial Interests, Personal, Funding, Travel support: AbbVie. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.